Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
Holding KURA?
Track your performance easily
KURA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.17 - $24.17
Previous Close$17.52
Volume1.45M
Average Volume (3M)542.32K
Market Cap
$1.36B
Enterprise Value$890.07M
Total Cash (Recent Filing)$491.52M
Total Debt (Recent Filing)$16.73M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Nov 07, 2024EPS Estimate
-$0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.23
Shares Outstanding76,634,496
10 Day Avg. Volume794,444
30 Day Avg. Volume542,321
Standard Deviation0.17
R-Squared0.07
Alpha0.00457
Financial Highlights & Ratios
Price to Book (P/B)2.71
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.52
Forecast
1Y Price Target
$29.82Price Target Upside67.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Kura Oncology News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsZiftomenib's potential for combinations with standard of care in both newly diagnosed and relapsed/refractory AML populations is reinforced by recent abstracts.
Financial PerformanceKura has a cash position of $491.5 million, indicating a strong financial standing.
Preclinical DataPreclinical data supports the development of Kura's menin inhibitor, ziftomenib, for treating advanced gastrointestinal stromal tumors (GIST).
Bears Say
Clinical DataEarly clinical NPM1 data is inconclusive on KURA vs SNDX, and both management teams set the same bar in r/r NPM1.
Drug ResistanceMany patients develop resistances to imatinib due to acquired secondary KIT mutations, highlighting the need for new therapeutic options.
Financial PerformanceKura reported no revenue, highlighting potential financial instability.
---
Ownership Overview
1.19% Insiders
11.07% Mutual Funds
1.99% Other Institutional Investors
72.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $8.17 and its highest was $24.17 in the past 12 months.
What is Kura Oncology’s market cap?
Currently, no data Available
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Nov 07, 2024 which is 2 days ago.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Aug 08, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.626 by $0.036.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -$0.63.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 76,634,500 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.626. Following the earnings report the stock price went down -0.785%.
Which hedge fund is a major shareholder of Kura Oncology?
Among the largest hedge funds holding Kura Oncology’s share is Deerfield Management Company, LP. It holds Kura Oncology’s shares valued at 111M.
---
Kura Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.82 (67.15% Upside)
$29.82 (67.15% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 79.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
94.45%
12-Months-Change
Fundamentals
Return on Equity
-39.27%
Trailing 12-Months
Asset Growth
4.12%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
---
KURA Company Deck
---
KURA Earnings Call
Q2 2024
0:00 / 0:00
---
KURA Stock 12 Month Forecast
Average Price Target
$29.82
▲(67.15% Upside)
Technical Analysis
Best Analysts Covering KURA
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
+31.81%
reiterated a buy rating 4 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +31.81% per trade.
---